The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today
announced the U.S. launch of PREBOOST® (topical 4% benzocaine
wipes) that helps in the prevention of premature ejaculation
(PE).
PREBOOST® is a new, proprietary over-the-counter (OTC) male
genital desensitizer that helps in temporarily prolonging the time
until ejaculation in men with premature ejaculation.
PREBOOST® is compliant with the relevant FDA monograph and is
approved for sale in the United States. PREBOOST® is the only
individually packaged medicated wipe that contains a desensitizing
agent (benzocaine 4.0%). Unlike currently available OTC
desensitizing sprays or gels that contain lidocaine or benzocaine,
PREBOOST® is an individually packaged wipe containing 4%
benzocaine, which allows for discrete, direct and precise
application of the correct dosage each time. It is applied
topically and dries quickly which prevents the potential for
transference to a partner.
The product is now available and can be purchased through the
e-commerce site http://preboost.com. The site includes
information about PREBOOST®, including how to apply the product, as
well as frequently asked questions (FAQs) and tips for better sex
with a partner.
“I invented PREBOOST® to help the millions of men who suffer
from PE and for those couples that want to extend their sexual
pleasure,” said Dr. Harry Fisch, the Company’s Chief Corporate
Officer “We believe PREBOOST® has significant advantages over
currently available therapies, especially with regard to ease of
use, delivery system and convenience.”
“Premature ejaculation is a large and underserved market,” said
Mitchell Steiner, M.D. President and Chief Executive Officer of The
Female Health Company / Veru Healthcare. “We are using
targeted digital, social media marketing and online optimization
capabilities to drive traffic to the PREBOOST® e-commerce
site. The next phase of launch will be to include a sampling
program targeting urologists, engaging a marketing partner to
co-promote PREBOOST®, introducing the product to large chain
pharmacies and other OTC distribution outlets, and seeking out
licensing opportunities for markets outside the U.S.”
“In my opinion, PREBOOST® is the only over-the-counter product
that has the clinical data that shows that it prolongs ejaculation
time based on an interim analysis of a well-designed placebo
controlled study with statistically significant results,” said
Ridwan Shabsigh, M.D., Professor of Urology at Weill Cornell
Medical College and President of the International Society of Men’s
Health.
As previously announced, the Company reported top line interim
analysis of an independent, double-blind, randomized, controlled
clinical study of PREBOOST®. The scientific abstract that
describes the full interim analysis results has been submitted to a
major urological medical conference.
The independent clinical study was conducted by Jed Kaminetsky,
M.D., Medical Director at Manhattan Medical Research, Clinical
Assistant Professor of Urology at New York University Medical
Center, and practicing urologist with University Urology
Associates; Michael Yang, Clinical Research Coordinator at
Manhattan Medical Research and University Urology Associates;
Michael Perelman. M.D., Clinical Professor Emeritus of Psychology
in Psychiatry at Weill Cornell Medical College; and, Ridwan
Shabsigh, M.D., Professor of Urology at Weill Cornell Medical
College, and President of the International Society of Men’s
Health. The clinical study was funded but not conducted by
Veru Healthcare.
The top line results of the interim analysis from 21 men
show:
- After two months, men treated with PREBOOST® had statistically
significant improvement in their ability to control ejaculation,
with a mean increase in duration of almost four minutes, which was
significantly greater than men on placebo. After treatment
with PREBOOST, 80% of men were no longer considered to have
PE;
- Men treated with PREBOOST® reported a statistically significant
better sense of ejaculation control, confidence, satisfaction,
sexual pleasure, length of intercourse and reduced
frustration;
- PREBOOST® was well tolerated and no transference was reported;
and
- The interim clinical study met the primary endpoint of change
in average intravaginal ejaculatory latency time (IELT) at two
months and secondary outcomes of change in questionnaire
assessments, such as global rating of distress, medication
assessment, and Index of Premature Ejaculation (IPE).
The Company said the interim results in men with PE show that
PREBOOST® prolonged time to ejaculation in men who suffer from
PE.
About Premature Ejaculation (PE):PE is defined
by the International Society for Sexual Medicine as persistent or
recurrent ejaculation with minimal sexual stimulation before, on,
or shortly after penetration and before the person wishes it.
PE is the most common sexual dysfunction, even more common than
erectile dysfunction, according to numerous epidemiological
studies. It is a problem for couples and the most commonly
observed sexual disorder in men below 40 years of age. PE is
a self-reported diagnosis with a prevalence rate of 20-30
percent. The estimated prevalence of PE is 50 million men in
the US and 60 million men in Europe. Total worldwide market
for premature ejaculation drugs and consumer health care products
is estimated to be greater than $500 million annually.
About PREBOOST®:PREBOOST® is a
new, proprietary OTC male genital desensitizer used for the
treatment of PE. There are no prescription products for PE
approved by the FDA. Off label use of antidepressants and
PDE-5 inhibitors have been used with limited success because of
inconsistent efficacy and unacceptable side effects.
Psychological counseling and behavioral therapy are also used
with mixed results. Of the consumer health products, the
topical anesthetics are administered as sprays and gels. The
drawbacks of these approaches include inconsistent dosing leading
to too much anesthetic and transference of the anesthetics to the
partner. PREBOOST® is compliant with the relevant FDA
monograph and is approved for sale in the United States.
PREBOOST® is the only individually packaged medicated wipe that
contains a desensitizing agent (benzocaine 4.0%). The
advantages are: 1) Convenient individually wrapped wipes so it is
easier to carry and to be discreet, 2) The correct dose is
delivered each time, 3) The medicine is applied topically and dries
quickly which prevents the potential for transference to partner,
and 4) Benzocaine at 4.0% temporarily desensitizes, but does not
numb, the penis.
PREBOOST® is now available and can be purchased through the
e-commerce site http://preboost.com.
About The Female Health Company / Veru
HealthcareThe Female Health Company / Veru Healthcare is a
medical therapeutics company, with a focus on the development and
commercialization of pharmaceuticals that qualify for the FDA's
505(b)(2) accelerated regulatory approval pathway as well as the
505(b)(1) pathway. The Company does business both as "Veru
Healthcare" and as "The Female Health Company" and is organized as
follows:
- Veru Healthcare manages the Pharmaceuticals Division, which
develops and commercializes pharmaceutical products for men's and
women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices
Division, which is focused on commercializing sexual healthcare
products and devices for the consumer market, including the
Company's Female Condom (FC2), which is referred to as the FC2
Female Condom® in the consumer health products sector and as the
Female Disposable Contraceptive Device (FC2) in the U.S.
prescription market, and PREBOOST® medicated individual wipes which
is a male genital desensitizing drug product that helps in the
prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health
Division, which is focused on the global public health sector FC2
business. This division markets the Company’s Female Condom
(FC2) to entities, including ministries of health, government
health agencies, U.N. agencies, nonprofit organizations and
commercial partners, that work to support and improve the lives,
health and well-being of women around the world.
More information about the Female Health Company and its
products can be found at www.femalehealth.com,
www.veruhealthcare.com and www.femalecondom.org. For
corporate and investor-related information about the Company,
please visit www.FHCinvestor.com.
"Safe Harbor" statement under the Private Securities
Litigation Reform Act of 1995:The statements in this
release which are not historical fact are "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. These statements are based
upon the Company's current plans and strategies, and reflect the
Company's current assessment of the risks and uncertainties related
to its business, and are made as of the date of this release.
The Company assumes no obligation to update any forward-looking
statements contained in this release as a result of new information
or future events, developments or circumstances. Such
forward-looking statements are inherently subject to known and
unknown risks and uncertainties. The Company's actual results
and future developments could differ materially from the results or
developments expressed in, or implied by, these forward-looking
statements. Factors that may cause actual results to differ
materially from those contemplated by such forward-looking
statements include, but are not limited to, the following:
demand and market acceptance of PREBOOST®; competition in the
Company's markets and the risk of new competitors and new
competitive product introductions; risks relating to the ability of
the Company to obtain sufficient financing on acceptable terms when
needed to fund development and operations; risks related to the
development of the Company's product portfolio, including clinical
trials, regulatory approvals and time and cost to bring to market;
many of the Company's products are at an early stage of development
and the Company may fail to successfully commercialize such
products; the length, cost and uncertain results of the Company’s
clinical trials; the potential of adverse side effects or other
safety risks that could preclude the approval of the Company’s
product candidates; risks related to intellectual property,
including licensing risks; government contracting risks, including
the appropriations process and funding priorities, potential
bureaucratic delays in awarding contracts, process errors, politics
or other pressures, and the risk that government tenders and
contracts may be subject to cancellation, delay or restructuring; a
governmental tender award indicates acceptance of the bidder's
price rather than an order or guarantee of the purchase of any
minimum number of units, and as a result government ministries or
other global public health sector customers may order and purchase
fewer units than the full maximum tender amount; the Company's
reliance on its international partners in the consumer sector and
on the level of spending on the female condom by country
governments, global donors and other public health organizations in
the global public health sector; the economic and business
environment and the impact of government pressures; the Company's
reliance on its major customers and risks related to delays in
payment of accounts receivable by major customers; risks involved
in doing business on an international level, including currency
risks, regulatory requirements, political risks, export
restrictions and other trade barriers; the Company's production
capacity, efficiency and supply constraints; risks related to the
costs and other effects of litigation; the Company's ability to
identify and successfully negotiate and complete suitable
acquisitions or other strategic initiatives; the Company's ability
to successfully integrate acquired businesses, technologies or
products; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission
filings, including the Company's Form 10-K for the year ended
September 30, 2016. These documents are available on the "SEC
Filings" section of our website at
www.femalehealth.com/investors.
Contact:
Kevin Gilbert 312-366-2633
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024